Cell & Gene Therapy (CGT) – Advisory Only
The CGT revolution in India is accelerating, but the gap between "marketing claims" and "clinical readiness" is vast. A single misstep in vector yield, capsid purity, or tech transfer can derail your program.
Strategic Governance for the Future of Medicine: CGT in India
Cell & Gene Therapy (CGT) – Advisory Only
Cell & Gene Therapies demand flawless execution, yet India's nascent ecosystem amplifies risks: overstated capabilities, titer variability, and regulatory grey zones.
Aventiq Bio specializes in advisory-only services - stress-testing selected partners for plasmid production, viral vectors, analytics, and tech transfer - enabling you to leverage India's talent depth and 50–70% cost advantages with eyes wide open.
-
Yield Gap & Capsid Variability
Low vector titers and poor empty-vs-full capsid ratios from unoptimized processes
-
Raw Material Trap
Unreliable local sourcing of high-grade pDNA, media, or transfection reagents
-
Facility Maintenance Culture
Cleanrooms claiming GMP but lacking sustained ISO class compliance or operator discipline.
-
Regulatory Grey Zones
Aligning evolving Indian RCGM/CDSCO rules with FDA/EMA ATMP standards.
-
Tech Transfer "Blind Spots"
Potency loss or impurity spikes during process handover
India's Evolving CGT Ecosystem – Talent-Driven Potential
India's CGT landscape is clinical-scale focused, with 10+ facilities excelling in plasmid DNA, AAV/lentiviral vectors, and advanced analytics (ddPCR, flow cytometry). The real strength lies in a massive pool of molecular biologists and virologists - delivering high-quality data at fraction of Western costs. Commercial-scale is emerging (2026–2028), making it ideal for early-phase and "China+1" strategies. Aventiq Bio scouts and evaluates these partners transparently, prioritizing analytical talent and process robustness.
Stress-Tested Guidance Across CGT Development Stages
We organize advisory around technical maturity stages - evaluating partners and planning for global readiness.
Partner ScoutingMaturity Benchmarking
- Scouting for plasmid/AAV/lentiviral facilities
- 50-point CGT Readiness Matrix scoring (infrastructure, talent, track record)
- The Aventiq Edge: Identifying the 1% truly capable today
Technical EvaluationPurity & Titer Audits
- Verifying empty-vs-full capsid ratios and HCP levels
- Analytical talent scouting (ddPCR, NGS, potency assays)
- The Aventiq Edge: Pre-identifying titer-drop risks before commitment
Regulatory BridgeGlobal ATMP Alignment
- Ensuring data acceptance by FDA/EMA (comparability, release testing)
- Capacity reservation advisory in limited-suite market
- The Aventiq Edge: Bridging Indian GMP with international ATMP guidelines
Tech Transfer Risk-Mapping Pre-Identifying Potency-Loss Risks
- Advisory for process handover (upstream/downstream)
- Raw material and supply chain evaluation
Why Choose Aventiq Bio for CGT
Many potent peptides fall under HPAPI classification (OEB 4–5 due to cytotoxicity). We extend our extreme containment expertise to these programs, ensuring safe synthesis, scale-up, and integration - particularly for oncology and ADC applications.
Independent auditor in a nascent market - no facility ties
Deep focus on analytical sensitivity and yield consistency
Proprietary maturity matrix for emerging partners
On-ground insights into talent and maintenance culture
Track record guiding early CGT programs globally